198 related articles for article (PubMed ID: 34930277)
1. m
Zhang B; Chen Z; Tao B; Yi C; Lin Z; Li Y; Shao W; Lin J; Chen J
Mol Cancer; 2021 Dec; 20(1):170. PubMed ID: 34930277
[TBL] [Abstract][Full Text] [Related]
2. A novel serum m
Chen Y; Xie Y; Bi L; Ci H; Li W; Liu D
Front Genet; 2024; 15():1270302. PubMed ID: 38384713
[No Abstract] [Full Text] [Related]
3. Construction of a serum diagnostic signature based on m5C-related miRNAs for cancer detection.
Tang F; Liu Y; Sun Y; Xiong Y; Gu Y; Zhou J; Ouyang Y; Zhang S
Front Endocrinol (Lausanne); 2023; 14():1099703. PubMed ID: 36777349
[TBL] [Abstract][Full Text] [Related]
4. Five serum-based miRNAs were identified as potential diagnostic biomarkers in gastric cardia adenocarcinoma.
Wang J; Zhang H; Zhou X; Wang T; Zhang J; Zhu W; Zhu H; Cheng W
Cancer Biomark; 2018; 23(2):193-203. PubMed ID: 30198863
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide study of salivary microRNAs as potential noninvasive biomarkers for detection of nasopharyngeal carcinoma.
Wu L; Zheng K; Yan C; Pan X; Liu Y; Liu J; Wang F; Guo W; He X; Li J; Shen Y
BMC Cancer; 2019 Aug; 19(1):843. PubMed ID: 31455274
[TBL] [Abstract][Full Text] [Related]
6. Circulating microRNA-422a is associated with lymphatic metastasis in lung cancer.
Wu L; Hu B; Zhao B; Liu Y; Yang Y; Zhang L; Chen J
Oncotarget; 2017 Jun; 8(26):42173-42188. PubMed ID: 28178679
[TBL] [Abstract][Full Text] [Related]
7. Two plasma microRNA panels for diagnosis and subtype discrimination of lung cancer.
Lu S; Kong H; Hou Y; Ge D; Huang W; Ou J; Yang D; Zhang L; Wu G; Song Y; Zhang X; Zhai C; Wang Q; Zhu H; Wu Y; Bai C
Lung Cancer; 2018 Sep; 123():44-51. PubMed ID: 30089594
[TBL] [Abstract][Full Text] [Related]
8. Identification of dysregulated serum miR-508-3p and miR-885-5p as potential diagnostic biomarkers of clear cell renal carcinoma.
Liu S; Deng X; Zhang J
Mol Med Rep; 2019 Dec; 20(6):5075-5083. PubMed ID: 31661117
[TBL] [Abstract][Full Text] [Related]
9. Identification of two microRNA signatures in whole blood as novel biomarkers for diagnosis of nasopharyngeal carcinoma.
Wen W; Mai SJ; Lin HX; Zhang MY; Huang JL; Hua X; Lin C; Long ZQ; Lu ZJ; Sun XQ; Liu SL; Yang Q; Zhu Q; Wang HY; Guo L
J Transl Med; 2019 Jun; 17(1):186. PubMed ID: 31159814
[TBL] [Abstract][Full Text] [Related]
10. A circulating miRNA signature as a diagnostic biomarker for non-invasive early detection of breast cancer.
Zhang L; Xu Y; Jin X; Wang Z; Wu Y; Zhao D; Chen G; Li D; Wang X; Cao H; Xie Y; Liang Z
Breast Cancer Res Treat; 2015 Nov; 154(2):423-34. PubMed ID: 26476723
[TBL] [Abstract][Full Text] [Related]
11. Identification of a six-miRNA panel in serum benefiting pancreatic cancer diagnosis.
Zou X; Wei J; Huang Z; Zhou X; Lu Z; Zhu W; Miao Y
Cancer Med; 2019 Jun; 8(6):2810-2822. PubMed ID: 31006985
[TBL] [Abstract][Full Text] [Related]
12. Potential circulating miRNA signature for early detection of NSCLC.
Arab A; Karimipoor M; Irani S; Kiani A; Zeinali S; Tafsiri E; Sheikhy K
Cancer Genet; 2017 Oct; 216-217():150-158. PubMed ID: 29025589
[TBL] [Abstract][Full Text] [Related]
13. Plasma microRNAs as potential new biomarkers for early detection of early gastric cancer.
Zhu XL; Ren LF; Wang HP; Bai ZT; Zhang L; Meng WB; Zhu KX; Ding FH; Miao L; Yan J; Wang YP; Liu YQ; Zhou WC; Li X
World J Gastroenterol; 2019 Apr; 25(13):1580-1591. PubMed ID: 30983818
[TBL] [Abstract][Full Text] [Related]
14. Identification of non-invasive biomarkers for chronic atrophic gastritis from serum exosomal microRNAs.
Liu H; Li PW; Yang WQ; Mi H; Pan JL; Huang YC; Hou ZK; Hou QK; Luo Q; Liu FB
BMC Cancer; 2019 Feb; 19(1):129. PubMed ID: 30736753
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the Diagnostic Efficiency of a Liquid Biopsy Assay for Early Detection of Gastric Cancer.
Izumi D; Zhu Z; Chen Y; Toden S; Huo X; Kanda M; Ishimoto T; Gu D; Tan M; Kodera Y; Baba H; Li W; Chen J; Wang X; Goel A
JAMA Netw Open; 2021 Aug; 4(8):e2121129. PubMed ID: 34427680
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of circulating miR-25-3p as a novel diagnostic and prognostic biomarker in osteosarcoma.
Fujiwara T; Uotani K; Yoshida A; Morita T; Nezu Y; Kobayashi E; Yoshida A; Uehara T; Omori T; Sugiu K; Komatsubara T; Takeda K; Kunisada T; Kawamura M; Kawai A; Ochiya T; Ozaki T
Oncotarget; 2017 May; 8(20):33375-33392. PubMed ID: 28380419
[TBL] [Abstract][Full Text] [Related]
17. Identification of a four-microRNA panel in serum for screening renal cell carcinoma.
Chen X; Li R; Li X; Peng X; Zhang C; Liu K; Huang G; Lai Y
Pathol Res Pract; 2021 Nov; 227():153625. PubMed ID: 34628264
[TBL] [Abstract][Full Text] [Related]
18. Radiogenomics Map Reveals the Landscape of m6A Methylation Modification Pattern in Bladder Cancer.
Ye F; Hu Y; Gao J; Liang Y; Liu Y; Ou Y; Cheng Z; Jiang H
Front Immunol; 2021; 12():722642. PubMed ID: 34733275
[TBL] [Abstract][Full Text] [Related]
19. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study.
Lin XJ; Chong Y; Guo ZW; Xie C; Yang XJ; Zhang Q; Li SP; Xiong Y; Yuan Y; Min J; Jia WH; Jie Y; Chen MS; Chen MX; Fang JH; Zeng C; Zhang Y; Guo RP; Wu Y; Lin G; Zheng L; Zhuang SM
Lancet Oncol; 2015 Jul; 16(7):804-15. PubMed ID: 26088272
[TBL] [Abstract][Full Text] [Related]
20. Competitive learning suggests circulating miRNA profiles for cancers decades prior to diagnosis.
Keller A; Fehlmann T; Backes C; Kern F; Gislefoss R; Langseth H; Rounge TB; Ludwig N; Meese E
RNA Biol; 2020 Oct; 17(10):1416-1426. PubMed ID: 32456538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
